Inhaled Insulin Afrezza: 2025 Update and Who It Helps Most

What Is Afrezza?

Afrezza (technosphere insulin) is the only FDA-approved inhaled insulin available in the United States. Manufactured by MannKind Corporation and originally approved by the FDA in June 2014, Afrezza delivers human insulin directly into the lungs through a small, discreet inhaler device roughly the size of a whistle. Once inhaled, the insulin absorbs rapidly into the bloodstream through the lung's vast surface area — reaching peak action faster than any injectable rapid-acting insulin on the market.

For many people living with diabetes, Afrezza represents something genuinely different: mealtime insulin coverage without a needle, without pre-meal injection timing anxiety, and with a pharmacokinetic profile that more closely mimics the body's natural insulin response after eating.

How Afrezza Works — And Why It's Different

Traditional rapid-acting injectable insulins like lispro (Humalog), aspart (NovoLog), and glulisine (Apidra) reach peak blood levels roughly 60–90 minutes after injection. Afrezza, by contrast, peaks in approximately 12–15 minutes and is largely cleared from the body within 3 hours. This ultra-rapid onset and shorter duration means less "insulin stacking" — a common problem where overlapping doses of injected insulin cause late hypoglycemia hours after a meal.

The technology behind this speed is MannKind's Technosphere platform — a proprietary fumaryl diketopiperazine (FDKP) particle carrier that rapidly dissolves in the lung's slightly acidic environment, releasing insulin for fast absorption. The inhaler itself uses pre-loaded single-use cartridges in 4-unit, 8-unit, and 12-unit doses (with combinations used for higher doses).

What the Clinical Evidence Shows

The pivotal trials supporting Afrezza's approval — including the AFFINITY 1 and AFFINITY 2 studies — demonstrated that Afrezza effectively lowered post-meal blood glucose in both Type 1 and Type 2 diabetes. In AFFINITY 1, Type 1 patients using Afrezza plus basal insulin achieved similar A1C reductions compared to those using injectable mealtime insulin, while experiencing significantly less hypoglycemia overall.

The STAT study (Study of Technosphere Insulin Action and Timing) published in Diabetes Care confirmed Afrezza's remarkably fast pharmacokinetic profile, showing insulin levels rising within 2–3 minutes of inhalation — faster than any injectable formulation. This makes it uniquely suited for covering rapid glucose spikes from high-glycemic meals.

More recent real-world data published between 2022 and 2024 from MannKind's expanded access programs and registry studies have shown Afrezza performing particularly well in Type 1 diabetes patients using automated insulin delivery (AID) systems and CGM. Some endocrinologists now use Afrezza specifically as a "rescue" correction bolus when CGM shows a rapidly rising glucose that would otherwise take 20–30 minutes to be addressed by an injected dose.

Who Benefits Most From Afrezza?

Based on clinical evidence and real-world experience, Afrezza tends to help the following groups most:

• People with significant needle phobia — Afrezza eliminates mealtime injections entirely (though a basal insulin injection is still needed for Type 1)
• Type 1 patients with unpredictable meals — Because of its fast onset and short duration, Afrezza can be dosed during or even after eating, reducing the risk of hypoglycemia from overestimating carbohydrates
• Type 2 patients resistant to starting insulin — Studies show higher acceptance rates when the delivery method is needle-free
• People who experience significant post-meal spikes — Afrezza's rapid peak action blunts glucose excursions more effectively than injectable rapid-acting insulins in many patients
• CGM users needing rapid corrections — The speed advantage is particularly valuable when managing glucose in real-time

Important Limitations and Contraindications

Afrezza is not appropriate for everyone. The FDA requires lung function testing (spirometry) before prescribing, and Afrezza is contraindicated in patients with chronic lung disease, including asthma and COPD, due to the risk of acute bronchospasm. Smokers are also excluded. A small but measurable decline in FEV1 (a measure of lung function) has been observed in some long-term users, though this appears to stabilize and partially reverse after discontinuation.

Dosing is less precise than injectable insulin — the cartridge system means doses come in fixed increments, which can make fine-tuning difficult for sensitive patients. Cost and insurance coverage remain significant barriers; without coverage, Afrezza can be expensive, though MannKind has patient assistance programs available.

Current Status (2025)

As of 2025, Afrezza remains FDA-approved and commercially available in the United States. MannKind Corporation continues to market and distribute it independently after the company's prior partnership with Sanofi ended in 2016. Prescriptions have grown steadily among endocrinology practices with experience using it, though overall market penetration remains modest compared to injectable rapid-acting insulins.

MannKind is actively exploring expanded applications of its Technosphere platform beyond diabetes, including inhaled treprostinil (Tyvaso DPI) for pulmonary hypertension — validating the platform's broader potential. No major new Phase 3 trials for Afrezza itself are currently registered on ClinicalTrials.gov as of early 2025, though observational and registry studies continue. Patients interested in current studies can search ClinicalTrials.gov using the terms "inhaled insulin" or "Afrezza" to find any newly registered protocols.

What This Means for Patients

If you have Type 1 or Type 2 diabetes, struggle with mealtime injections, experience significant post-meal glucose spikes, or have had recurring hypoglycemia from injectable mealtime insulin, Afrezza is worth a serious conversation with your endocrinologist. It is a real, approved, available option — not experimental.

Before starting, your doctor will need to perform spirometry to confirm adequate lung function. If approved, most patients find the inhaler intuitive to use within one or two sessions of training. Some adjustment of basal insulin doses may be needed as mealtime glucose control improves.

For patients already using CGM systems or reviewing their current insulin and diabetes supplies, resources at mdsdiabetes.com can help you compare mealtime insulin options and understand how Afrezza fits into a broader diabetes management plan. The most important step is working with a diabetes care team experienced with inhaled insulin — dosing strategies and real-world expectations differ enough from injectable insulin that hands-on guidance makes a meaningful difference in outcomes.